Pediatrix Medical Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Pediatrix provides physician services in newborn, maternal-fetal, pediatric cardiology, and other pediatric specialties across 37 states. Financial statements are unaudited.
Key financial results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net revenue | $495.1 million | $491.0 million | Up 0.8% |
| Income from operations | $15.9 million | $30.0 million | Down 47.1% |
| Operating margin | 3.2% | 6.1% | Down 2.9 percentage points |
| Net income | $4.0 million | $14.2 million | Down $10.2 million |
| Diluted EPS | $0.05 | $0.17 | Down $0.12 |
| Adjusted EBITDA (non-GAAP) | $37.2 million | $40.1 million | Down $2.8 million |
| Adjusted EPS (non-GAAP) | $0.20 | $0.23 | Down $0.03 |
Revenue growth reflected a $10.9 million, or 2.3%, increase in same-unit revenue, partly offset by lower non-same-unit revenue. Same-unit growth comprised higher patient-service volume ($6.4 million) and net reimbursement-related factors ($4.5 million), including increased hospital administrative fees. Patient-service revenue declined slightly to $421.8 million from $423.2 million; hospital contract administrative fees rose to $71.8 million from $66.0 million.
Practice salaries and benefits rose 1.9% to $369.1 million, primarily due to higher clinical compensation. General and administrative expense increased to $60.2 million; as a share of revenue it rose to 12.2% from 12.0%. The effective tax rate was 48.4%, including $1.7 million of discrete tax expense; excluding discrete items, the company reported a 27.0% rate.
Cash flow, liquidity, and debt
- Cash and cash equivalents were $8.0 million at March 31, 2024, down from $73.3 million at year-end. Short-term investments were $107.5 million, for cash plus short-term investments of approximately $115.5 million.
- Working capital was $179.2 million, up $84.7 million from year-end, primarily due to net line-of-credit borrowings.
- Cash used in operating activities from continuing operations was $122.6 million, versus $100.6 million in Q1 2023. Including discontinued operations, total operating cash used was $125.2 million. Cash used in investing was $16.2 million; financing provided $76.2 million.
- Operating cash flow was affected by the annual first-quarter payment of performance-based incentive compensation and weaker collections. Continuing-operations DSO was 52.2 days, versus 50.5 days at December 31, 2023 and 51.1 days a year earlier.
- At quarter-end, principal debt outstanding was $705 million: $400 million of 5.375% senior notes due 2030 and $305 million under the credit agreement ($225 million term loan and $80 million revolver). The company reported $370 million available under the credit agreement.
- The company said it was in material compliance with debt covenants and expected to remain compliant through 2024. It believes operating funds, cash, and available credit will cover working capital, expected acquisitions, capital expenditures, restructuring costs, repurchases, and contractual obligations for at least the next 12 months.
Material changes, outlook, and risks
- Margins and earnings weakened: Operating income fell as expenses grew faster than revenue, including higher clinical compensation and $8.5 million of transformational and restructuring costs. Those costs primarily related to position eliminations and revenue-cycle-management transition activities. Excluding them, management reported operating income of $24.4 million and a 4.9% operating margin.
- Management commentary: Adjusted EBITDA declined mainly because of higher same-unit operating expenses. The filing provides no specific revenue, earnings, or margin guidance.
- Acquisition: Pediatrix acquired one maternal-fetal medicine practice for $9.7 million of consideration: $6.5 million paid at closing and $3.2 million recorded as contingent consideration.
- Reimbursement and collections: Nearly all patient-service revenue is paid by government programs and third-party insurers. Management noted lower reimbursement from government programs compared with commercial payors, potential shifts in payor mix, rising patient responsibility, and collection/bad-debt risks. Contracted managed care represented 70% of patient-service revenue, government payors 25%.
- Regulatory and legal exposure: The No Surprises Act and related state rules may constrain out-of-network payments; independent dispute-resolution outcomes remain uncertain. The company also faces ordinary-course government audits and investigations, malpractice claims, and other litigation. It self-insures a portion of professional-liability exposure; the recorded professional-liability liability was $284.9 million, with a $33.2 million insurance receivable for certain covered claims. Management said outcomes cannot be predicted with certainty and coverage may be inadequate.
- Interest-rate sensitivity: A 1% rate change on credit-agreement borrowings would affect annual pretax income by approximately $3.1 million. Credit facilities include leverage and interest-coverage covenants.
- The company reported no material changes to the risk factors in its 2023 Form 10-K. Disclosure controls were considered effective as of March 31, 2024.
Important facts for investors to verify
- Whether DSO and collections improve, and whether the elevated accounts-receivable balance affects future operating cash flow.
- Whether restructuring produces durable expense savings and recovery in operating margins, beyond the company’s non-GAAP adjustments.
- How payor mix, reimbursement rates, hospital administrative fees, and No Surprises Act dispute outcomes affect revenue and collections.
- Debt, revolver usage, covenant headroom, and liquidity needs, particularly given low cash balances and first-quarter cash outflows.
- Development of professional-liability claims, government inquiries, and acquisition-related contingent consideration.